We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+10.86%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$5.06B
AUM Growth
–
Cap. Flow
+$4.02B
Cap. Flow %
79.47%
Top 10 Hldgs %
79.91%
Holding
75
New
67
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$880M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$674M
3
GHDX
Genomic Health, Inc.
GHDX
+$448M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$420M
5
INCY icon
Incyte
INCY
+$324M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 39.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGYP
26
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$11.3M 0.22%
+2,644,787
New +$13.3M
CHTP
27
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$11M 0.22%
+4,775,787
New +$9.66M
PTLA
28
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$9.83M 0.19%
+399,914
New +$7.95M
INSM icon
29
Insmed
INSM
$22.4B
$9.52M 0.19%
+795,803
New +$8.13M
IRWD icon
30
Ironwood Pharmaceuticals
IRWD
$586M
$9.16M 0.18%
+1,101,059
New +$13.3M
BCRX icon
31
BioCryst Pharmaceuticals
BCRX
$2.42B
$8.62M 0.17%
+5,563,615
New +$9.6M
MTEM
32
DELISTED
Molecular Templates, Inc.
MTEM
$8.39M 0.17%
+9,667
New +$8.17M
MDGL icon
33
Madrigal Pharmaceuticals
MDGL
$12.6B
$6.98M 0.14%
+39,973
New +$10.4M
ARRY
34
DELISTED
Array Biopharma Inc
ARRY
$6.81M 0.13%
+1,500,000
New +$8.07M
QLTI
35
DELISTED
QLT Inc
QLTI
$6.74M 0.13%
+1,535,863
New +$12.4M
IONS icon
36
Ionis Pharmaceuticals
IONS
$8.93B
$6.64M 0.13%
+247,036
New +$5.25M
CCXI
37
DELISTED
ChemoCentryx, Inc.
CCXI
$5.3M 0.1%
+375,000
New +$4.86M
AMBI
38
DELISTED
Ambit Biosciences Corp
AMBI
$5.24M 0.1%
+747,962
New +$5.35M
XNPT
39
DELISTED
XENOPORT, INC.
XNPT
$5.12M 0.1%
+1,034,112
New +$6.27M
ANAC
40
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$4.9M 0.1%
+876,463
New +$5.31M
PRTA icon
41
Prothena Corp
PRTA
$448M
$4.77M 0.09%
+369,650
New +$3.44M
KYTH
42
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$4.46M 0.09%
+165,000
New +$3.78M
ACHN
43
DELISTED
Achillion Pharmaceuticals
ACHN
$3.72M 0.07%
+455,000
New +$3.47M
PBYI icon
44
Puma Biotechnology
PBYI
$398M
$3.7M 0.07%
+83,333
New +$2.94M
LITS
45
Lite Strategy Inc
LITS
$32.4M
$3.68M 0.07%
+25,781
New +$4.29M
BDSI
46
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.66M 0.07%
+900,505
New +$4.23M
ZGNX
47
DELISTED
Zogenix, Inc.
ZGNX
$3.42M 0.07%
+250,125
New +$3.2M
SLXP
48
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$3.02M 0.06%
+45,571
New +$2.61M
ACGN
49
DELISTED
Aceragen Inc
ACGN
$2.95M 0.06%
+33,121
New +$2.98M
ASMB icon
50
Assembly Biosciences
ASMB
$498M
$2.92M 0.06%
+20,264
New +$3.18M
1
2
3

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Baker Bros. Advisors, which disclosed 75 positions worth $5.06B. Its ten largest holdings account for 80% of the portfolio.

Its largest position is PHARMACYCLICS INC: 10,771,138 shares worth $856M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets.

  • Baker Bros. Advisors's largest Q2 2013 buy was PHARMACYCLICS INC: 10,771,138 shares worth $856M.
  • Baker Bros. Advisors's ten largest holdings make up 80% of its $5.06B portfolio in Q2 2013.
  • Baker Bros. Advisors disclosed 75 positions in Q2 2013, its first 13F filing on record.

Based on Baker Bros. Advisors's 13F filing for Q2 2013, filed 14 Aug 2013.